Suven Life Sciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	71.15	66.56	116.93	135.39	118.44
Other Revenue	139.3	-	-	0.56	1.06
Revenue	210.45	66.56	116.93	135.95	119.51
Revenue Growth (YoY)	216.19%	-43.08%	-13.99%	13.76%	-15.08%
Cost of Revenue	-	7.51	8.24	5.66	24.33
Gross Profit	210.45	59.05	108.69	130.29	95.18
Selling, General & Admin	241.49	211.17	190.24	186.21	210.21
Research & Development	2,482	1,440	1,144	1,154	1,064
Other Operating Expenses	192.8	61.96	52.08	45.56	39.53
Operating Expenses	2,972	1,771	1,452	1,451	1,357
Operating Income	-2,762	-1,712	-1,343	-1,320	-1,262
Interest Expense	-	-0.47	-1.58	-2.89	-5.32
Interest & Investment Income	-	56.83	164.25	64.16	11.26
Currency Exchange Gain (Loss)	-	-2.27	-0.7	-3.28	-3.71
Other Non Operating Income (Expenses)	-1.58	0.62	0	-	0
EBT Excluding Unusual Items	-2,763	-1,657	-1,181	-1,262	-1,260
Gain (Loss) on Sale of Investments	-	49.76	45.49	17.92	3.56
Asset Writedown	-	-	-	-0.02	-0.86
Other Unusual Items	-	-	0.11	1.85	0.13
Pretax Income	-2,763	-1,607	-1,061	-1,183	-1,220
Income Tax Expense	-	-	-10.02	-	-
Net Income	-2,763	-1,607	-1,051	-1,183	-1,220
Net Income to Common	-2,763	-1,607	-1,051	-1,183	-1,220
Shares Outstanding (Basic)	228	218	218	178	135
Shares Outstanding (Diluted)	228	218	218	178	135
Shares Change (YoY)	4.47%	-	22.31%	32.29%	5.88%
EPS (Basic)	-12.13	-7.37	-4.82	-6.63	-9.05
EPS (Diluted)	-12.13	-7.37	-4.82	-6.63	-9.05
Free Cash Flow	-3,069	-1,914	-1,155	-1,189	-1,473
Free Cash Flow Per Share	-13.47	-8.78	-5.29	-6.67	-10.93
Dividend Per Share	-	-	-	-	1.000
Gross Margin	100.00%	88.71%	92.95%	95.84%	79.64%
Operating Margin	-1312.37%	-2572.07%	-1148.48%	-971.27%	-1056.14%
Profit Margin	-1313.12%	-2415.11%	-898.63%	-869.95%	-1020.82%
Free Cash Flow Margin	-1458.17%	-2875.39%	-987.51%	-874.42%	-1232.64%
EBITDA	-2,706	-1,659	-1,285	-1,262	-1,227
D&A For EBITDA	56.14	52.78	57.89	58	35.41
EBIT	-2,762	-1,712	-1,343	-1,320	-1,262
Revenue as Reported	210.45	175.53	328.23	219.88	134.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.